Reviva Pharmaceuticals Holdings Inc. (RVPH) is a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for central nervous system (CNS) disorders and other critical health issues. The company’s lead candidate, RP5063, presents a unique therapeutic strategy for managing schizophrenia and mood disorders, supported by an innovative drug delivery platform that aims to improve treatment efficacy. Reviva is well-positioned for growth in the dynamic mental health sector, with a robust pipeline and a strong focus on addressing significant unmet medical needs as it navigates key clinical development milestones.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-10.10M |
| Operating Margin | 0.00% |
| Return on Equity | -256.20% |
| Return on Assets | -69.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.47 |
| Price-to-Book | 0.29 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -6.00 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $13.11M |
| Float | $11.34M |
| % Insiders | 1.90% |
| % Institutions | 27.72% |
CUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD.
CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.
- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in mid-2026 - - Initiation of patient enrollment in RECOVER-2 registrational Phase 3 trial expected Q3 2026 -
